The medicines exist to treat diabetes successfully and affordably, even in the poorest settings. But today there are tens of millions of people living with diabetes who cannot get the life-saving insulin that they need – because it is too costly alongside other necessities in life, or in some parts of the world isn’t on the shelf when it is needed.
As the world’s biggest producer of medicines for diabetes, we stand on the frontline of the challenge of affordability and availability. It’s our ambition that everyone who needs our essential medicines can access them, at prices that they can afford.
In 2019, 5.1 million people with diabetes treated with our human insulin at a maximum of 4 USD per 10ml vial
Our Changing Diabetes in Children® programme has reached 25,600+ children and adolescents with type 1 diabetes
In 2019, we donated 86 million Danish Kroner to the World
When we determine how to price our medicines, we consider a number of country specific factors: the value that the medicine brings to patients, how the medicine compares with alternative treatments for the same disease, the local healthcare system and other socio-economic factors.
Insulin is a special case. For people with type 1 diabetes and for some people with type 2 diabetes, it is an essential, life-saving medicine for which there is no alternative. It’s our ambition that everyone who needs insulin has access to it at prices they can afford.
Our Access to Insulin Commitment guarantees that we will provide low-priced human insulin for people living with diabetes in low- and middle-income countries.
Today, our commitment covers 76 countries, home to 124 million people with diabetes, as well as selected humanitarian organisations operating in crisis areas.
We recognise that some people with diabetes in the United States are increasingly finding it hard to pay for their healthcare, including our diabetes medicines.
Ensuring access and affordability is a responsibility we share with all involved in healthcare and we are going to do our part.
The diabetes challenge hits underserved communities the hardest, especially those in low- and middle-income countries. When barriers to medicine and basic healthcare put people living with diabetes at risk of developing complications such as heart disease, blindness, kidney damage and amputations.
Our efforts in low- and middle-income countries focus on people who
are the most vulnerable and we have put in place affordability and
access programmes in over two-thirds of the countries where we
We are working through a growing range of partnerships to expand our efforts and embed solutions into our day-to-day business.
Through a combination of our programmes and partnerships, we are helping people access the care they need, no matter where they live.
In 2002, we established the World Diabetes Foundation to invest hundreds of millions of dollars in the prevention and treatment of diabetes in low- and middle-income countries.
The Foundation’s network of public and private partners have helped shape the system of support for people with diabetes in countries around the world.
The Novo Nordisk Haemophilia Foundation (NNHF) is a grant-making, non-profit organisation that strives to improve access to care for people with haemophilia and allied bleeding disorders in developing and emerging countries.
Haemophilia is a hereditary bleeding disorder affecting one in 10,000 people. 75% of people with haemophilia live in the developing world, where most do not have a diagnosis or access to adequate care.